Does Hurler Syndrome MPS1H have a cure?

Currently, there is no definitive cure for Hurler Syndrome (MPS1H), which is the most severe form of Mucopolysaccharidosis type I. While treatments such as Hematopoietic Stem Cell Transplantation (HSCT) and Enzyme Replacement Therapy (ERT) can significantly modify the disease course and improve quality of life, they do not reverse all existing damage or fully correct the underlying genetic deficiency.

What is the current standard of care for Hurler Syndrome?

Management of Hurler Syndrome focuses on slowing disease progression and managing symptoms. Early intervention is critical. The standard of care often involves a combination of:

• Hematopoietic Stem Cell Transplantation (HSCT): When performed early (ideally before age 2), HSCT can provide a source of healthy enzymes, significantly slowing cognitive decline and improving long-term outcomes for children with Hurler Syndrome.


• Enzyme Replacement Therapy (ERT): Weekly infusions of laronidase help manage non-neurological symptoms, such as organ enlargement and joint stiffness, though it does not cross the blood-brain barrier to treat neurological symptoms effectively.

What research is being done to find a cure for Hurler Syndrome?

Researchers are actively investigating next-generation therapies to overcome the limitations of current treatments. The primary focus is on gene therapy, which aims to deliver a functional copy of the IDUA gene to the patient’s cells. By enabling the body to produce its own enzymes, these therapies strive to achieve more consistent, systemic, and potentially neurological correction than standard Hurler Syndrome treatments.

Are there clinical trials for Hurler Syndrome?

Yes, clinical research is ongoing. Scientists are exploring:

• In vivo gene therapy: Using viral vectors to deliver functional genes directly into the bloodstream or central nervous system.


• Ex vivo gene therapy: Modifying a patient's own stem cells in a laboratory before reintroducing them.


• Next-generation enzyme delivery: Developing molecules engineered to cross the blood-brain barrier more efficiently.

Next steps

• Consult with a metabolic geneticist or a specialist center experienced in Hurler Syndrome to discuss eligibility for current clinical trials.


• Register with the National MPS Society or DiseaseMaps.org to connect with 7 other families who share their experience with Hurler Syndrome.


• Monitor ClinicalTrials.gov regularly for new updates on Hurler Syndrome research phases.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult with your healthcare team regarding your specific clinical situation.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Mucopolysaccharidosis type I


• Orphanet: Hurler syndrome


• OMIM (Online Mendelian Inheritance in Man): Mucopolysaccharidosis type IH


• National MPS Society: MPS I Information and Resources